The discovery of Ku–DNA binding inhibitors as a new and innovative strategy for DNA-PK inhibition has enabled us to explore an alternative approach for cellular sensitization to current cancer therapies, making Ku–DNA binding inhibitors potentially valuable for use in cancer therapeutics. This evidence concerns the gene PRKDC and cancer.